These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11799926)

  • 21. Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland.
    Ip C; Thompson HJ; Ganther HE
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):49-54. PubMed ID: 10667463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor inflammatory angiogenesis and its chemoprevention.
    Albini A; Tosetti F; Benelli R; Noonan DM
    Cancer Res; 2005 Dec; 65(23):10637-41. PubMed ID: 16322203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase.
    Ganther HE
    Carcinogenesis; 1999 Sep; 20(9):1657-66. PubMed ID: 10469608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S; Olson TA; Bautch VL; Mohanraj D
    Cancer Res; 1996 Mar; 56(6):1324-30. PubMed ID: 8640821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprevention with triphenylselenonium chloride in selenium-deficient rats.
    Ip C; Lisk DJ; Ganther HE
    Anticancer Res; 2000; 20(6B):4179-82. PubMed ID: 11205245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular chemoprevention by selenium: a genomic approach.
    El-Bayoumy K; Sinha R
    Mutat Res; 2005 Dec; 591(1-2):224-36. PubMed ID: 16099479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selenium and anticarcinogenesis: underlying mechanisms.
    Jackson MI; Combs GF
    Curr Opin Clin Nutr Metab Care; 2008 Nov; 11(6):718-26. PubMed ID: 18827575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y; Wang S; Hoot DR; Clinton SK
    J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selenium: a double-edged sword for defense and offence in cancer.
    Brozmanová J; Mániková D; Vlčková V; Chovanec M
    Arch Toxicol; 2010 Dec; 84(12):919-38. PubMed ID: 20871980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
    Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
    Brantley DM; Cheng N; Thompson EJ; Lin Q; Brekken RA; Thorpe PE; Muraoka RS; Cerretti DP; Pozzi A; Jackson D; Lin C; Chen J
    Oncogene; 2002 Oct; 21(46):7011-26. PubMed ID: 12370823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence of a field effect associated with mammary cancer chemoprevention by methylseleninic acid.
    Dong Y; Ip C; Ganther H
    Anticancer Res; 2002; 22(1A):27-32. PubMed ID: 12017302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.
    Bauer KS; Cude KJ; Dixon SC; Kruger EA; Figg WD
    J Pharmacol Exp Ther; 2000 Jan; 292(1):31-7. PubMed ID: 10604929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of mammary cancer chemoprevention by organoselenium compounds.
    El-Bayoumy K; Sinha R
    Mutat Res; 2004 Jul; 551(1-2):181-97. PubMed ID: 15225592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.
    Lin P; Sankar S; Shan S; Dewhirst MW; Polverini PJ; Quinn TQ; Peters KG
    Cell Growth Differ; 1998 Jan; 9(1):49-58. PubMed ID: 9438388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.